Clinical trials: White Blood Cells
Eosinophilic Esophagitis (EoE)
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
- Trial name
- NCT06598462
- Testing
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose
- Where
- 73 sites in United States, Australia and 7 more
- Volunteers
- 184 people
- Sponsor
- Uniquity One (UNI)
Chronic Obstructive Pulmonary Disease
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
This was an exploratory, randomized, subject- and investigator-blind, placebo-controlled, parallel group, proof-of-mechanism study of multiple oral doses of fevipiprant (QAW039) in chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03810183
- Testing
- QAW039
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Asthma, Bronchial
Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
This is an exploratory, randomized, subject- and investigator-blinded, placebo-controlled mode-of-action study to demonstrate the anti-inflammatory effects of fevipiprant compared to placebo after 12 weeks of treatment in 48…
- Conditions
- Asthma, Asthma, Bronchial, Bronchial Asthma, Eosinophilia
- Trial name
- NCT03989635
- Testing
- QAW039
- Sponsor
- Novartis Pharmaceuticals
LPS Challenge, Neutrophils
Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge
Study to investigate the effect of a single dose of AZD7624 on inflammation caused by an endotoxin challenge.
- Trial name
- NCT01937338
- Testing
- AZD7624
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
Mepolizumab is a humanized monoclonal antibody (IgG1, kappa) that blocks interleukin- 5 (IL-5) thus inhibits production and survival of eosinophils.
- Trial name
- PRISM (NCT04276233)
- Testing
- Mepolizumab, Salbutamol
- Where
- 14 sites in India
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous lirentelimab (AK002), given monthly for 6 doses, in…
- Trial name
- ENIGMA-SC (NCT05152563)
- Testing
- AK002
- Where
- 76 sites in United States
- Sponsor
- Allakos Inc.
Leukocyte Adhesion Deficiency, Type II
Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II
Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II
- Trial name
- NCT03354533
- Testing
- L-fucose
- Volunteers
- 4 people
- Sponsor
- Orpha Labs
Eosinophilic Asthma
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma.
- Trial name
- NCT03469934
- Testing
- Etokimab
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- AnaptysBio, Inc.
HIV Infections
Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects
To conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.
- Trial name
- NCT00002018
- Testing
- Interferon alfa-n3
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Interferon Sciences
Breast Cancer
Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis
Double blind, randomized, placebo-controlled, multicenter pilot study on efficacy and safety of CBLB612 following single administration for neutropenia prophylaxis in breast cancer patients receiving doxorubicin and…
- Trial name
- NCT02778763
- Testing
- CBLB612
- Volunteers
- 23 people
- Sponsor
- BioLab 612 LLC
Eosinophilic Esophagitis
Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
This will be a randomised, double blind, placebo controlled, parallel group evaluation of the effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.
- Trial name
- NCT01056783
- Testing
- OC000459
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- Oxagen Ltd
Severe Eosinophilic Asthma
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Severe eosinophilic asthma (SEA) is associated with poor disease control and compromised health-related quality of life (HRQoL), leading to a substantial psychosocial and economic disease burden.
- Trial name
- EMPOWAIR (NCT05440656)
- Testing
- Cohort
- Where
- 13 sites in Greece
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Aspergillus Infection, Febrile Neutropenia
Ampholipad Real-World Data in Taiwan
A retrospective, post-marketing, multi-center chart review study includes patients who had been prescribed Ampholipad.
- Conditions
- Aspergillus Infection, Febrile Neutropenia, Candida Infection, Fungal Infection
- Trial name
- NCT03641131
- Where
- 6 sites in Taiwan
- Volunteers
- 102 people
- Sponsor
- Taiwan Liposome Company
HIV Infections
Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients
To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate…
- Trial name
- NCT00002012
- Testing
- Interferon alfa-n3
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Interferon Sciences
Asthma; Eosinophilic
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.
- Trial name
- PERSEA (NCT04049175)
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Bulgaria
- Volunteers
- 810 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Urinary Tract Infection, Diabetes Mellitus
Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station
The study objective is to satisfy the testing requirements for the Qualcomm Tricorder XPRIZE Competition. This requires an oversight model using the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station to…
- Conditions
- Urinary Tract Infection, Diabetes Mellitus, Atrial Fibrillation, OSA
- Trial name
- NCT02856633
- Testing
- Vitaliti
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cloud DX Inc.
Neutropenia
Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis
This open-labelled, single arm study is a follow-on from Study MPG010 to compare the relative bioavailability of Lozanoc 65 mg Capsules against Lozanoc 50 mg Capsules and Sporanox 100 mg Capsules in patients requiring…
- Trial name
- NCT02755857
- Testing
- Lozanoc
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Mayne Pharma International Pty Ltd
Leukocytosis
Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion
This study is a multicenter, retrospective data collection of routine clinical use with the Spectra Optia® apheresis system for white blood cell depletion.
- Trial name
- WBCD (NCT02302365)
- Testing
- Spectra Optia® Apheresis System
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Terumo BCT